Vered Stearns
Johns Hopkins University · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Eastern Cooperative Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
22
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
NIH RePORTER
Trial papers
77
PubMed author-name match
Trials
Studies that name Vered Stearns as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:41 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02965755 · Personalized Molecular Profiling in Cancer Treatment at Johns HopkinsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Metastatic Breast Cancer · principal investigator
- Ph2NCT02738866 · Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Metastatic Breast Cancer · study chair
- N/ANCT01939847 · IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns HopkinsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Breast Cancer · principal investigator
- N/ANCT01937052 · Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal DatabaseSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · study chair
- N/ANCT01871116 · POWER-remote Weight Loss Program in Early Stage Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Early Stage Breast Cancer · study chair
- N/ANCT01824836 · A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)ECOG-ACRIN Cancer Research Group · active not recruiting · Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer · principal investigator
- Ph2NCT01763931 · DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · study chair
- Ph2NCT01349959 · Azacitidine and Entinostat in Treating Patients With Advanced Breast CancerNational Cancer Institute (NCI) · completed · Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7 · principal investigator
- Ph2NCT01194427 · A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer · principal investigator
- Ph2NCT01194440 · Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal SymptomsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer · principal investigator
- Ph2NCT01124695 · Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast CancerECOG-ACRIN Cancer Research Group · completed · Breast Cancer, Stage IV Breast Cancer · principal investigator
- N/ANCT00897338 · Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · principal investigator
- Ph2NCT00616967 · Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Breast Cancer · study chair
- N/ANCT00373191 · Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By SurgerySidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · principal investigator
- Ph2NCT00354640 · Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · principal investigator
- Ph2NCT00334542 · Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · principal investigator
- Ph1NCT00290732 · Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · study chair
- Ph2NCT00262834 · Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast CancerNational Cancer Institute (NCI) · completed · Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer · principal investigator
- N/ANCT00249847 · Study of PET Scans and Serotonin in Hot Flashes TreatmentSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Hot Flashes · principal investigator
- Ph2NCT00244959 · Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Breast Cancer · study chair
- Ph2NCT00080626 · Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Breast Cancer · principal investigator
- Ph2NCT00003035 · Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast CancerGeorgetown University · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Breast and Ovarian Cancer Program - 08P30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2017 to 2021 · $36,923 awarded in 2021Grant number is on one of their registry trials
- YOUNG WOMEN WITH BREAST CANCER PROGRAM AT JOHNS HOPKINS: SURVIVING AND THRIVINGU58DP005410 · NCCDPHP · JOHNS HOPKINS UNIVERSITY · fiscal years 2014 · $340,322 awarded in 2014Same name and institution; not confirmed by an ID
- THE EFFECTS OF 24 MONTHS OF EXEMESTANE OR LETROZOLE ON SURROGATE MARKERSM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · fiscal years 2007 · $2,251 awarded in 2007Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG - ACRIN CCOP RESEARCH BASE GRANT - COREU10CA037403 · NCI · DREXEL UNIVERSITY · PI ROBERT L COMIS · fiscal years 2007 to 2014Named on NCT01824836
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA099168 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI EDWARD CHU · fiscal years 2007 to 2013Named on NCT01349959
- Phase I Clinical Trials of New Anti-Cancer Targeted TherapiesU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI Michael A Carducci · fiscal years 2007 to 2013Named on NCT01349959, NCT00262834
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2014 to 2026Named on NCT01349959
- ECOG-ACRIN Network Group Statistics and Data Management CenterU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · fiscal years 2014 to 2026Named on NCT01124695
- SPORE in Breast CancerP50CA088843 · NCI · JOHNS HOPKINS UNIVERSITY · PI Sara Sukumar · fiscal years 2006 to 2010Named on NCT00334542, NCT00080626
- Cancer Research Training and Education CoordinationP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Rebecca B Riggins · fiscal years 2006 to 2026Named on NCT00003035
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:41 UTC. The ranking covers the 200 most relevant of 77 PubMed records, and a shared surname and initials can bring in a namesake. All 77 on PubMed
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.J Natl Cancer Inst · 2003662 citationsRCR 16.6
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med · 2014578 citationsRCR 16.9
- Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.Clin Cancer Res · 2013569 citationsRCR 15.6
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.N Engl J Med · 2018529 citationsRCR 20.2
- 366 citationsRCR 10.1
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.Oncotarget · 2014357 citationsRCR 8.9
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.J Clin Oncol · 2015335 citationsRCR 9.5
- Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.J Clin Oncol · 2012314 citationsRCR 8.9
- Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.J Clin Oncol · 2013197 citationsRCR 5.1
- Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.Breast Cancer Res Treat · 2008191 citationsRCR 4.7